Recent Updates
Recently added Catalysts

Hepatocellular Carcinoma: 5 biotech companies with clinical-stage programmes

OncologyConcentrated betData as of 2026-09-04

Competitors5in the clinic
Median market cap$2.1Buniverse median $1.20B
Allocated capital$7.3B$28.2B competing
Phase 3 or filed12 mid, 2 early
Pure plays2this indication only
Capital rank24/299crowding rank 33

Hepatocellular Carcinoma is a concentrated bet: only 5 US-listed developers are in the clinic, and the median one is worth $2.1B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

EXEL carries 52% of the $28.2B competing here, more than the other 4 companies combined.

$7.3B of allocated capital sits in Hepatocellular Carcinoma, 24th of 299 indications, and 2 of the 5 companies are pure plays that trade on this indication alone.

Companies developing drugs for Hepatocellular Carcinoma 5

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
EXELExelixisSorafenibPhase 33$14.7BNo11 3 Dec 2026
REPLReplimune GroupRP2Phase 21$1.3BNo4 31 Dec 2030
CHRSCoherus OncologyCasdozokitugPhase 21$212MYes1 31 Dec 2026
ABVXAbivaxABX196Phase 11$9.9BNo3 31 Dec 2026
ZYMEZymeworksZW251Phase 11$2.1BYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. EXEL holds 52% of the $28.2B competing in this indication.

Why Hepatocellular Carcinoma is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Hepatocellular Carcinoma has 5 competitors and a median of $2.1B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Acute Myeloid Leukemia15 companies · $7.0B · median $1.2BKnife fightSmall Cell Lung Cancer8 companies · $6.7B · median $2.0BGold rushOvarian Cancer9 companies · $6.7B · median $1.4BGold rushColorectal Cancer7 companies · $5.9B · median $723MKnife fightHead and Neck Cancer7 companies · $5.5B · median $1.8BGold rushBladder Cancer8 companies · $9.1B · median $1.8BGold rushBiliary Tract Cancer4 companies · $4.6B · median $7.4BConcentrated betWell-differentiated Non-functional Neuroendocrine Tumor1 company · $4.5B · median $9.0BUncontested

Hepatocellular Carcinoma pipeline questions

Which biotech companies are developing drugs for Hepatocellular Carcinoma?

Exelixis (EXEL, Sorafenib, Phase 3); Replimune Group (REPL, RP2, Phase 2); Coherus Oncology (CHRS, Casdozokitug, Phase 2); Abivax (ABVX, ABX196, Phase 1); Zymeworks (ZYME, ZW251, Phase 1). Those are the 5 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Hepatocellular Carcinoma.

How advanced is the Hepatocellular Carcinoma pipeline?

Of the 5 clinical-stage programmes in Hepatocellular Carcinoma, 1 is in Phase 3 or filed, 2 are in mid-stage development and 2 are in early-stage development.

Which company leads the Hepatocellular Carcinoma field?

EXEL is the largest developer in Hepatocellular Carcinoma, holding 52% of the $28.2B of market capitalisation competing in the indication. The median competitor is worth $2.1B.

When is the next Hepatocellular Carcinoma catalyst?

The next dated catalyst in Hepatocellular Carcinoma is EXEL on 3 Dec 2026. 4 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map